Research programme: anti-L1 monoclonal antibodies - MediGene/German Cancer Research Center

Drug Profile

Research programme: anti-L1 monoclonal antibodies - MediGene/German Cancer Research Center

Latest Information Update: 30 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator German Cancer Research Center
  • Developer Celltrion; MediGene AG
  • Class Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jul 2008 MediGene and Celltrion agree to co-promote and co-develop the products in Asia for Cancer
  • 17 Jul 2008 Products licensed to Medigene worldwide for the treatment of Cancer
  • 12 Mar 2008 Preclinical development for cancer is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top